Isotechnika said data from a Canadian Phase III trial for its immunosuppressive drug, ISA247 met all primary and secondary effectiveness endpoints at 12 weeks with minimal side effects.
The trial of 453 patients with stable moderate to severe plaque psoriasis was conducted at 32 sites over a 24 week period using orally administered ISA247 in psoriasis patients.
"Our goal was to create a drug with a superior safety and efficacy profile compared to other medications used to treat psoriasis," Isotechnika president and chief operating officer Randall Yatscoff said in a release.
"We are pleased to have achieved these goals in the interim data analysis which indicates the presence of a therapeutic window. It is very encouraging to see that our 24-week endpoints were achieved at the 12 week point of the trial."
